‘Compugen’: Positive Results For Cancer Treatment Protein

Compugen announced positive results for its trial of CGEN-15022, a membrane protein that was discovered by the company, as a treatment of multiple cancers such as liver, colorectal, lung and ovarian cancers. According to the company, the results indicate the potential of the protein as a compelling drug target for treatment of these cancers through monoclonal antibody (mAb) therapy. Compugen is a product discovery company focused on therapeutic proteins and monoclonal antibodies, based in Tel Aviv, Israel.